- Tigermed’s net income for the fiscal year missed the estimated target.
- The net income stood at 2.02 billion yuan, while it was estimated to be 2.35 billion yuan.
- The total revenue was 7.38 billion yuan, falling short of the estimated 7.84 billion yuan.
- Revenue from Clinical Trial Solutions was 4.17 billion yuan, less than the expected 4.34 billion yuan.
- The company received 22 buys, 4 holds, and 4 sells.
A look at Hangzhou Tigermed Consulting (A) Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Hangzhou Tigermed Consulting (A) has been given a Smartkarma Smart Score of 3 out of 5 for its overall outlook. This indicates that the company has a moderate outlook, with some areas showing potential for growth and resilience.
The company, which provides clinical research services for pharmaceutical and health-related research and development, has received a score of 3 for value, dividend, and growth. This means that Hangzhou Tigermed Consulting (A) has been performing moderately well in these areas. However, it has scored a 4 for resilience, indicating that the company may be able to weather any potential challenges in the future. On the other hand, its momentum score of 2 suggests that the company may not be experiencing significant growth at the moment.
Overall, Hangzhou Tigermed Consulting (A) has received a moderate Smartkarma Smart Score, indicating that it may be a stable and reliable company with some potential for growth and resilience. However, investors should keep an eye on its momentum score and monitor any changes in the company’s performance in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
